Trial Profile
An Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Sepofarsen (Primary)
- Indications Leber congenital amaurosis
- Focus Adverse reactions; First in man
- Sponsors ProQR Therapeutics
- 01 May 2022 Results assessing sepofarsen safety and tolerability via the frequency and severity of ocular adverse events (AEs) published in the Nature Medicine
- 24 Sep 2020 According to an ProQR Therapeutics media release, data from this trial will be presented at the European Society of Retina Specialists (Euretina) congress.
- 08 Jun 2020 According to an ProQR Therapeutics media release, data from this study will be shared via a video presentation through the Association for Research in Vision and Ophthalmology (ARVO). Due to COVID-19, the ARVO 2020 Annual Meeting was cancelled and instead video-recorded presentations will be available on ARVOLearn, starting June 15, 2020.